Flash Sale! to get a free eCookbook with our top 25 recipes.

The Janssen Pharmaceutical Companies announced the acquisition of all rights to Bermekimab, along with certain employees, from XBiotech Inc., for $750 million. The Janssen Pharmaceutical Companies of Johnson & Johnson announced the completion of the acquisition of all rights to the investigational compound Bermekimab, which has multiple dermatological indications, along with certain employees, from XBiotech Inc., for $750 million. Should ...